News

Under the terms of the agreement, Lilly will acquire all of the outstanding shares of SGX common stock at a price of $3 per share, for a total

The FDA granted the orphan drug status based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the

Over the next several weeks, TomoTherapy and Hi-Art will negotiate a definitive purchase agreement. The transaction is expected to close in the fourth quarter of 2008, at which

The Phase I study succeeded in meeting both its primary and secondary objectives. The primary objectives were to evaluate the safety and tolerability and to assess the pharmacokinetics

Tim Clover, CEO of t+ Medical Holdings, and Andrew Hall, founder and managing director of Vivatec, in a joint statement said: “This acquisition enables t+ Medical to expand

The study by the Merck Serono division will assess the clinical benefit of the targeted cancer therapy Erbitux (cetuximab) in combination with cisplatin and capecitabine as a first-line

The culture media covered by this patent contain the key combination of two or three types of enzyme inhibitor. Professor Smith discovered that by inhibiting certain key enzymes

The facility, built as a result of a co-operative agreement between the company and the University Business Park, is an advanced construction, linked to Ark’s existing manufacturing and

Under the terms of the license agreement with Cancer Research Technology (CRT), ValiRx has a period of 12 months in which to complete the pre-clinical regulatory development of